Form 4 for INKT MiNK Therapeutics, Inc.

Accepted 2021-10-20 00:00:00 ET · period of report 2021-10-19 · accession 0000899243-21-040873 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2021-10-20	2021-10-19	INKT	AGENUS INC	10%	C - Cnv Deriv	—	-5.45M	26.33M	-17%	—
D	2021-10-20	2021-10-19	INKT	AGENUS INC	10%	P - Purchase	$12.00	+1.40M	20.88M	+7%	+$16.80M
D	2021-10-20	2021-10-19	INKT	AGENUS INC	10%	C - Cnv Deriv	—	-5.45M	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-10-19	C	D	5,451,958	—	26,332,958	D	—	—	(F2) The shares were received upon the automatic conversion of a convertible promissory note issued to Agenus Inc. by the issuer upon completion of the Issuer's initial public offering. The conversion rate of the note was equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the common stock sold in the initial public offering.
2	Common	Common Stock	2021-10-19	P	A	1,400,000	$12.00	20,881,000	D	—	—
3	Derivative	Convertible Promissory Note	2021-10-19	C	D	5,451,958	—	0	D	— · 2021-10-19 to 2022-07-01	5,451,958 Common Stock	(F2) The shares were received upon the automatic conversion of a convertible promissory note issued to Agenus Inc. by the issuer upon completion of the Issuer's initial public offering. The conversion rate of the note was equal to the quotient obtained by dividing (i) the amount due on the date of conversion by (ii) 80% of the per share price of the common stock sold in the initial public offering.